

# Javier Vázquez-Bourgon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5018606/publications.pdf>

Version: 2024-02-01

78  
papers

1,083  
citations

471509

17  
h-index

501196

28  
g-index

91  
all docs

91  
docs citations

91  
times ranked

1911  
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
2	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	7.2	127
3	Genetic variants associated with longitudinal changes in brain structure across the lifespan. <i>Nature Neuroscience</i> , 2022, 25, 421-432.	14.8	75
4	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	11.0	44
5	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. <i>JAMA Psychiatry</i> , 2019, 76, 864.	11.0	43
6	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 217-229.	2.1	40
7	Main determinants of Global Assessment of Functioning score in schizophrenia: a European multicenter study. <i>Comprehensive Psychiatry</i> , 2005, 46, 440-446.	3.1	36
8	Understanding sex differences in long-term outcomes after a first episode of psychosis. <i>NPJ Schizophrenia</i> , 2020, 6, 33.	3.6	36
9	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. <i>Psychopharmacology</i> , 2018, 235, 245-255.	3.1	30
10	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. <i>Human Brain Mapping</i> , 2022, 43, 300-328.	3.6	30
11	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 189-194.	3.3	29
12	Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 646701.	3.5	24
13	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. <i>Psychiatry Research</i> , 2011, 185, 286-289.	3.3	23
14	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. <i>Science Advances</i> , 2019, 5, eaau9093.	10.3	22
15	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109677.	4.8	20
16	A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2020, 39, 46-55.	0.7	19
17	Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. <i>Journal of Psychopharmacology</i> , 2019, 33, 284-294.	4.0	18
18	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1090-1101.	2.1	16

#	ARTICLE	IF	CITATIONS
19	Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. <i>Translational Psychiatry</i> , 2019, 9, 306.	4.8	16
20	A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis. <i>Psychiatry Investigation</i> , 2014, 11, 186.	1.6	16
21	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 673-682.	4.1	15
22	Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. <i>Psychological Medicine</i> , 2021, 51, 264-277.	4.5	15
23	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
24	Brain grey matter abnormalities in first episode non-affective psychosis patients with suicidal behaviours: The role of neurocognitive functioning. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109948.	4.8	14
25	The synergetic effect of childhood trauma and recent stressful events in psychosis: associated neurocognitive dysfunction. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 43-51.	4.5	13
26	Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 1-7.	2.1	12
27	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. <i>Schizophrenia Research</i> , 2020, 220, 240-247.	2.0	11
28	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. <i>Biological Psychiatry</i> , 2022, 92, 299-313.	1.3	11
29	Intraoperative Identification and Preservation of Verbal Memory in Diffuse Gliomas. <i>Neurosurgery</i> , 2018, 83, 1209-1218.	1.1	9
30	La estimulación cerebral profunda en el trastorno obsesivo-compulsivo refractario al tratamiento: una revisión sistemática. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 37-51.	1.8	9
31	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, 14, 157-163.	1.8	9
32	Cross-Modal Recruitment of Auditory and Orofacial Areas During Sign Language in a Deaf Subject. <i>World Neurosurgery</i> , 2017, 105, 1033.e1-1033.e5.	1.3	7
33	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. <i>Journal of Psychiatric Research</i> , 2021, 134, 150-157.	3.1	7
34	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. <i>European Neuropsychopharmacology</i> , 2021, 47, 74-85.	0.7	7
35	Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis. <i>Brain Imaging and Behavior</i> , 2016, 10, 629-635.	2.1	6
36	Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up. <i>Schizophrenia Research</i> , 2018, 201, 159-166.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6106.	4.1	6
38	Prolactin, metabolic and immune parameters in naïve subjects with a first episode of psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110332.	4.8	6
39	Community alternatives to acute inpatient care for severe psychiatric patients. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 323-32.	0.1	6
40	Deep brain stimulation and treatment-resistant obsessive-compulsive disorder: A systematic review. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2019, 12, 37-51.	0.3	5
41	Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort. <i>Psychological Medicine</i> , 2022, 52, 770-779.	4.5	5
42	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 795-806.	2.1	5
43	Effect of DISC1 Polymorphisms on the Long-term Course of Neurocognitive Deficits in Non-affective Psychosis. <i>European Psychiatry</i> , 2015, 30, 861-867.	0.2	4
44	Diferencias en la efectividad clínica y funcional, entre trastornos psiquiátricos, de un hospital de día psiquiátrico de agudos para pacientes con enfermedad mental aguda. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, 14, 40-49.	1.8	4
45	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021, 14, 157-163.	0.3	4
46	Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3-year longitudinal study. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 578-588.	4.5	4
47	Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 301-2.	0.6	4
48	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 37-49.	4.1	4
49	Disability multilevel modelling in first episodes of psychosis at 3-year follow-up. <i>Schizophrenia Research</i> , 2017, 185, 101-106.	2.0	3
50	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. <i>Data in Brief</i> , 2019, 27, 104415.	1.0	3
51	Predictors of weight acquisition induced by antipsychotic treatment and its relationship with age in a sample of first episode non-affective psychosis patients: A three-year follow-up study. <i>Schizophrenia Research</i> , 2020, 222, 462-464.	2.0	3
52	A network analysis approach to functioning problems in first psychotic episodes and their relationship with duration of untreated illness: Findings from the PAFIP cohort. <i>Journal of Psychiatric Research</i> , 2021, 136, 483-491.	3.1	3
53	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. <i>Psychological Medicine</i> , 2023, 53, 1891-1905.	4.5	3
54	A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research. <i>Schizophrenia Research</i> , 2022, 243, 467-469.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. <i>Schizophrenia Research</i> , 2022, 246, 30-38.	2.0	3
56	Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort. <i>Schizophrenia Research</i> , 2021, 232, 28-30.	2.0	2
57	Differences between psychiatric disorders in the clinical and functional effectiveness of an acute psychiatric day hospital, for acutely ill psychiatric patients. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2021, 14, 40-49.	0.3	2
58	The Early Phases of Anxiety Disorders: From Prevention to Treatment. <i>Modern Problems of Pharmacopsychiatry</i> , 2013, 29, 98-110.	2.5	1
59	44 Real World Effectiveness: A 6-month Naturalistic Follow-up Study of Schizophrenia Patients After Switching to Aripiprazole Monohydrate (AOM) Treatment. <i>CNS Spectrums</i> , 2019, 24, 199-200.	1.2	1
60	Predictive value of prolactin in first episode psychosis at ten years follow-up. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2021, 14, 179-180.	1.8	1
61	Stability of schizophrenia diagnosis in a 10-year longitudinal study on first episode of non-affective psychosis: Conclusions from the PAFIP cohort. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 342-357.	4.5	1
62	Chapter 9 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2012, , 103-109.		1
63	Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532098149.	2.7	1
64	Metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2023, 16, 175-183.	1.8	1
65	Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort. <i>Journal of Psychiatric Research</i> , 2022, 153, 292-299.	3.1	1
66	5-HT2A POLYMORPHISMS AND NEGATIVE SYMPTOMATOLOGY: EVIDENCE OF ASSOCIATION IN FIRST EPISODE PSYCHOSIS PATIENTS. <i>Schizophrenia Research</i> , 2008, 102, 184.	2.0	0
67	SEROTONIN TRANSPORTER POLYMORPHISMS AND EARLY RESPONSE TO ANTIPSYCHOTIC TREATMENT IN FIRST-EPISODE OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2008, 102, 193.	2.0	0
68	DISRUPTED IN SCHIZOPHRENIA 1 GENOTYPE AND RESPONSE TO ANTIPSYCHOTICS IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 456.	2.0	0
69	T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S184-S184.	4.3	0
70	F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S259-S259.	4.3	0
71	SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS. <i>European Neuropsychopharmacology</i> , 2019, 29, S999.	0.7	0
72	F55INFLUENCE OF SCHIZOPHRENIA POLYGENIC RISK SCORES ON BRAIN SURFACE: AN EXPLORATORY STUDY IN FIRST EPISODE OF PSYCHOSIS. <i>European Neuropsychopharmacology</i> , 2019, 29, S1139.	0.7	0

#	ARTICLE	IF	CITATIONS
73	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. Data in Brief, 2020, 30, 105599.	1.0	0
74	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De Psiquiatr�a Y Salud Mental (English Edition), 2021, 14, 179-180.	0.3	0
75	Chapter 10 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2013, , 107-113.		0
76	Recovery of long-term paresis following resection of WHO grade II gliomas infiltrating the pyramidal pathway. Journal of Neurosurgical Sciences, 2016, 61, 88-96.	0.6	0
77	Incidence of COPD in a sample of patients with psychosis: preliminary data from a 10 years longitudinal study. , 2019, , .		0
78	Reduced glomerular filter rate in antipsychotic-na�ve patients with first-episode psychosis. Schizophrenia Research, 2022, 246, 202-204.	2.0	0